Entrectinib (Rozlytrek) for ROS1-positive Non-Small Cell Lung Cancer
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.